8 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
2021 was the first year that the Company has prepared a Remuneration Report and as the Company was incorporated on 7 January 2021, and we do not have any historical remuneration to disclose for periods prior to 2021.
| | Total remuneration $ | | | Annual bonus (percentage of target) | | | Share options vested during the year(1) | |
2023 | | | | | | | |||
Executive Director: | | | 1,403,204 | | | 110% | | | 1,240,914 |
Bahija Jallal | | | | | | | |||
| | | | | | ||||
2022 | | | | | | | |||
Executive Director: | | | 1,417,606 | | | 125% | | | 1,435,239 |
Bahija Jallal | | | | | | | |||
| | | | | | ||||
2021 | | | | | | | |||
Executive Director: | | | 1,266,024 | | | 100% | | | 920,397 |
Bahija Jallal | | | | | | |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
2021 was the first year that the Company prepared a Remuneration Report as the Company was incorporated on 7 January 2021, and we do not have any historical remuneration to disclose for periods prior to 2021.
| | Percentage change 2022-2023 | | | Percentage change 2021-2022 | |||||||||||||
| | Base salary / fees | | | Benefits | | | Bonus | | | Base salary / fees | | | Benefits | | | Bonus | |
Executive Directors | | | | | | | | | | | | | ||||||
Bahija Jallal | | | 5.0% | | | -1.7% | | | -7.6% | | | 0.0% | | | 49.1% | | | 25.0% |
Non-Executive Directors | | | | | | | | | | | | | ||||||
Professor Sir John Bell | | | 6.9% | | | — | | | — | | | 20.9% | | | — | | | — |
Travis Coy | | | — | | | — | | | — | | | — | | | — | | | — |
Roy Herbst, M.D., Ph.D. | | | 8.9% | | | — | | | — | | | 19.9% | | | — | | | — |
Robert Perez | | | — | | | — | | | — | | | — | | | — | | | — |
Kristine Peterson | | | 13.3% | | | — | | | — | | | 25.9% | | | — | | | — |
Professor Sir Peter Ratcliffe | | | 2.7% | | | — | | | — | | | 21.9% | | | — | | | — |
Siddharth Kaul | | | 87.7% | | | — | | | — | | | — | | | — | | | — |
Average pay of employees as a whole | | | 7.9% | | | 10.8% | | | 18.3% | | | 13.1% | | | 13.8% | | | 9.1% |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
For 2023, our corporate scorecard was comprised of performance objectives in three categories, with 50% of an executive’s bonus opportunity tied to the achievement of TCR innovation metrics, 40% tied to business growth metrics and 10% tied to workplace improvement metrics. The goals summarized below for each metric were selected by the remuneration committee based on the remuneration committee’s determination that each was important for our short- and long-term success. The remuneration committee set threshold (75% achievement for partially meeting the goal), target (100% achievement for meeting the goal) and maximum (125% achievement for exceeding the goal) performance levels for each goal. When it approved the 2023 performance objectives, the remuneration committee believed that achievement of target performance would be reasonably challenging based upon industry-wide conditions and our internal forecasts at the time. Further, the performance objectives were set within the backdrop of a difficult environment due to the Ukraine and Israel-Hamas wars and global geopolitical tensions. Our 2023 corporate scorecard and the relevant performance levels are summarized, for market factors and competitive reasons, below. The summary of our annual performance bonus design below includes the level of detail we believe we can disclose without creating competitive harm for the Company.
Metric | | | Weight | | | Goals | | | Achievement | | | Weighted Achievement |
Lead in TCR Innovation | | | 50% | | | Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory submissions, high impact publications and other related matters | | | 93% | | | 46.3% |
| | | | | | | | |||||
Grow the Business | | | 40% | | | Goals pertaining to commercial and other matters, including related to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development | | | 114% | | | 45.5% |
| | | | | | | | |||||
Be the Best Workplace | | | 10% | | | Goals related to recruiting, employee engagement, compliance, workforce planning, culture and other employee matters | | | 93% | | | 9.3% |
| | | | | | | | |||||
| | | | Initial Calculated Achievement | | | 101% | |||||
| | | | Adjusted Achievement for Exceeding Scorecard Goals (See Below) | | | 110% |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
The summary of our annual performance bonus design below includes the level of detail we believe we can disclose without creating competitive harm for the Company.
Metric | | | Weight | | | Goals | | | Achievement | | | Weighted Achievement |
Lead in TCR Innovation | | | 50% | | | Goals focused on executing our clinical trials, building our pipeline for new products, completing regulatory submissions, high impact publications and other related matters | | | 93% | | | 46.3% |
| | | | | | | | |||||
Grow the Business | | | 40% | | | Goals pertaining to commercial and other matters, including related to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development | | | 114% | | | 45.5% |
| | | | | | | | |||||
Be the Best Workplace | | | 10% | | | Goals related to recruiting, employee engagement, compliance, workforce planning, culture and other employee matters | | | 93% | | | 9.3% |
| | | | | | | | |||||
Initial Calculated Achievement | | | | | 101% | |||||||
| | | | | | | | |||||
Adjusted Achievement for Exceeding Scorecard Goals (See Below) | | | | | 110% |
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
Year ended 31 December 2022
Name | | | Salary and Fees $ | | | Benefits(1) $ | | | Pension (401(k)) $ | | | Total Fixed Remuneration $ | | | Annual Bonus(2) $ | | | Share- based Awards(3) $ | | | Total Variable Remuneration $ | | | Total Remuneration $ |
Executive Director: | | | | | | | | | | | | | | | | | ||||||||
Bahija Jallal, Ph.D. | | | 700,000 | | | 46,106 | | | 15,250 | | | 761,356 | | | 656,250 | | | — | | | 656,250 | | | 1,417,606 |
Non-Executive Directors: | | | | | | | | | | | | | | | | | ||||||||
Professor Sir John Bell | | | 85,288 | | | — | | | — | | | 85,288 | | | — | | | — | | | — | | | 85,288 |
Travis Coy(4) | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Roy Herbst, M.D., Ph.D. | | | 56,199 | | | — | | | — | | | 56,199 | | | — | | | — | | | — | | | 56,199 |
Robert Perez(4) | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — |
Kristine Peterson | | | 56,219 | | | — | | | — | | | 56,219 | | | — | | | — | | | — | | | 56,219 |
Professor Sir Peter Ratcliffe | | | 57,158 | | | — | | | — | | | 57,158 | | | — | | | — | | | — | | | 57,158 |
Siddharth Kaul | | | 32,610 | | | — | | | — | | | 32,610 | | | — | | | — | | | — | | | 32,610 |
Total director compensation | | | 987,474 | | | 46,106 | | | 15,250 | | | 1,048,830 | | | 656,250 | | | — | | | 656,250 | | | 1,705,080 |
DEF 14A
our 7tkalm
12 Apr 24
Definitive proxy
4:20pm
DEF 14A
xrvo0
12 Apr 24
Definitive proxy
4:20pm
DEF 14A
1yxm759t
12 Apr 24
Definitive proxy
4:20pm
- Prev
- 1
- Next